top of page

BTK Inhibitor Acalabrutinib Shows Early Promise for COVID-19

Acalabrutinib (Calquence, AstraZeneca), a Bruton tyrosine kinase (BTK) inhibitor, showed early signs it may improve outcomes quickly for patients with severe COVID-19, a case study of 19 patients has found.

The research was conducted by Mark Roschewski, MD, and colleagues with the Lymphoid Malignancies Branch of the National Cancer Institute (NCI) in Bethesda, Maryland, in collaboration with teams from the National Institute of Allergy and Infectious Diseases (NIAID); Walter Reed National Military Medical Center in Bethesda; and four other US hospitals.

The peer-reviewed results were published online June 5 in Science Immunology.

0 views0 comments

Recent Posts

See All
bottom of page